SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fischel JL, Formento P, Etienne MC, et al. In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol. 1990; 25: 337341.
  • 2
    Jacrot M, Giroux B, Deloffre P. Activity of nitrosourea fotemustine against a human glioma xenograft in the nude mouse. ECCO Proceedings 5, London, 1989.
  • 3
    Vassal G, Boland I, Terrier-Lacombe MJ, et al. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res. 1998; 4: 463468.
  • 4
    Ings RM, Breen M, Devereux K, et al. The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice. Cancer Chemother Pharmacol. 1990; 27: 106110.
  • 5
    Meulemans A, Giroux B, Hannoun P, Robine D, Henzel D. Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy. 1991; 37: 8692.
  • 6
    Meulemans A, Giroux B, Hannoun P, Henzel D, Bizzari JP, Mohler J. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy. 1989; 35: 313319.
  • 7
    Lucas C, Ings B, Gray AJ, et al. Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S 10036): mice, rats, monkeys, dogs and man. Bull Cancer. 1989; 76: 863865.
  • 8
    Khayat D, Lokiec F, Bizzari JP, et al. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res. 1987; 47: 67826785.
  • 9
    Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990; 66: 18731878.
  • 10
    Frenay M, Giroux B, Khoury S, Derlon JM, Namer M. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer. 1991; 27: 852856.
  • 11
    Malhaire JP, Lucas B, Simon H, Person H, Dam-Hieu P, Labat JP. Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas. Bull Cancer. 1999; 86: 289294.
  • 12
    Delepine N, Subovici H, Cornille B, Markowska S, Alkallaf S, Desbois JC. High effectiveness of fotemustine in cerebral tumours in children [Abstract]. Proc European Association of Neuro-oncology (EANO) J Neurooncol. 1994; 21: 47.
  • 13
    Carter SK, Schabel FM Jr., Broder LE, Johnston TP. 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res. 1972; 16: 273332.
  • 14
    Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks. Cancer Chemother Pharmacol. 1989; 23: 266267.
  • 15
    Friedman MA. PCNU phase I study in the North California Oncology Group. Recent Results Cancer Res. 1981; 76: 125129.
  • 16
    Gjedde SB, Mouridsen HT, Madsen E, et al. Phase I study of tauromustine administered in a weekly schedule. Eur J Cancer. 1993; 29A: 19011902.
  • 17
    Hoth D, Woolley P, Green D, Macdonald J, Schein P. Phase I studies on chlorozotocin. Clin Pharmacol Ther. 1978; 23: 712722.
  • 18
    Kim-Triana B, Misset JL, Madelmont JC, Godeneche D, Musset M, Mathe G. Phase I trial of perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme. Anticancer Drugs. 1992; 3: 225231.
  • 19
    Mathe G, Misset JL, Triana BK, Godeneche D, Madelmont JC, Meyniel G. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme. Drugs Exp Clin Res. 1992; 18: 155158.
  • 20
    Ogawa M. Phase I study of GANU and MCNU. Cancer Treat Rev. 1980; 7: 197203.
  • 21
    Smyth JF, Macpherson JS, Warrington PS, et al. Phase I study of TCNU, a novel nitrosourea. Eur J Cancer Clin Oncol. 1987; 23: 18451849.
  • 22
    Rall DP, Ben M, McCarthy DM. BCNU toxicity and initial clinical trial. Proc Am Assoc Cancer Res. 1963; 55.
  • 23
    Wasserman TH, Slavik M, Carter SK. Methyl-CCNU in clinical cancer therapy. Cancer Treat Rev. 1974; 1: 251269.
  • 24
    Iriarte PV, Hananian J, Cortner JA. Central nervous system leukemia and solid tumors of childhood. Treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Cancer. 1966; 19: 11871194.
  • 25
    Carter SK. Clinical trials in cancer chemotherapy. Cancer. 1977; 40: 544557.
  • 26
    Smith M, Bernstein M, Bleyer WA, et al. Conduct of phase I trials in children with cancer. J Clin Oncol. 1998; 16: 966978.
  • 27
    MacArthur CA, Vietti T. The importance of phase I/II trials in pediatric oncology. Invest New Drugs. 1996; 14: 3335.
  • 28
    Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD. Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep. 1985; 69: 12631269.
  • 29
    Biron P, Janvier M, Chauvin F, Mornex F, Berlion M, Giroux B. High-dose fotemustine with autologous bone marrow transplantation for high grade supratentorial malignant gliomas. A phase I-II study. Electronic J Oncol. 1999; 2: 6988.
  • 30
    Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol. 1997; 39: 376379.
  • 31
    Phillips GL, Fay JW, Herzig GP, et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I-II study. Cancer. 1983; 52: 17921802.
  • 32
    Marzolini C, Decosterd LA, Shen F, et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol. 1998; 42: 433440.
  • 33
    Boiardi A, Silvani A, Ciusani E, et al. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. J Neurooncol. 2001; 52: 149156.
  • 34
    Gander M, Leyvraz S, Decosterd L, et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol. 1999; 10: 831838.
  • 35
    Friedman HS, Dolan ME, Moschel RC, et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992; 84: 19261931.
  • 36
    Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32: 471476.
  • 37
    Sarkar A, Dolan ME, Gonzalez GG, Marton LJ, Pegg AE, Deen DF. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3- bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993; 32: 477481.
  • 38
    Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993; 67: 12991302.
  • 39
    Fairbairn LJ, Watson AJ, Rafferty JA, Elder RH, Margison GP. O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol. 1995; 23: 112116.
  • 40
    Allay JA, Koc ON, Davis BM, Gerson SL. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin Cancer Res. 1996; 2: 13531359.
  • 41
    Harris LC, Marathi UK, Edwards CC, et al. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin Cancer Res. 1995; 1: 13591368.
  • 42
    Fairbairn LJ, Rafferty JA, Lashford LS. Engineering drug resistance in human cells. Bone Marrow Transplant. 2000; 25 (Suppl 2): S110S113.
  • 43
    Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide. Cancer Gene Ther. 2000; 7: 233239.
  • 44
    Chinnasamy N, Rafferty J, Lashford L, et al. Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming ce. Leukemia. 1999; 13: 17761783.
  • 45
    Chinnasamy N, Fairbairn LJ, Laher J, Willington MA, Rafferty JA. Modulation of O6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells. Mutat Res. 1998; 416: 110.
  • 46
    Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 1982; 42: 43304331.
  • 47
    Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother. 2001; 2: 479489.
  • 48
    Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 2001; 92: 914923.
  • 49
    Mohr P, Makki A, Breitbart E, Schadendorf D. Combined treatment of stage IV melanoma patients with amifostine and fotemustine — a pilot study. Melanoma Res. 1998; 8: 166169.